Skip to content
BioLegacy Research
  • Services
    • col1
      • In Vitro Services
      • Pharmacology Services
      • Toxicology Services
    • col2
      • IND Process
      • Disease Models
      • Medical Device Testing
    • col3
      • Custom Services
      • Vivarium Space
      • Drug Development Process
      • Histology Services
  • About Us
  • News
  • Animal Species
  • Why BioLegacy
  • Request A Quote
  • Partnering
  • Contact
    • Careers

Archive for April 2022

European Commission Approves Six Additional Indications for Merck’s Keytruda

April 29, 2022

The European Commission has approved Merck’s blockbuster oncology drug Keytruda (pembrolizumab) for six new indications, including persistent, recurrent or metastatic cervical cancer. Source: Drug Industry Daily

Read More

GAO Officials Testify Before House Committee on Ensuring Scientific Integrity

April 29, 2022

Government Accountability Office (GAO) officials testified on Friday before a House subcommittee where they highlighted the lack of procedures in four public health agencies — including the FDA — for reporting potential political interference. Source: Drug Industry Daily

Read More

NovoNordisk’s Once-Weekly Insulin Controls Blood Sugar as Well as Daily Injections

April 29, 2022

NovoNordisk has reported that its once-a-week form of insulin controlled blood sugar as well as short-acting insulin with a similar rate of hypoglycemic events in a late-stage trial. Source: Drug Industry Daily

Read More

FDA Announces Dates for COVID-19 Vaccine AdComs Though No Full Applications Are In Yet

April 29, 2022

The FDA has announced tentative dates for its vaccine-related advisory committee to meet to discuss the much-anticipated full applications for Emergency Use Authorization (EUA) that it expects any day from COVID-19 vaccine manufacturers for children under age six. Source: Drug Industry Daily

Read More

Big Three COVID-19 Vaccine Maker Shareholders Vote No on Sharing Intellectual Property With LMICs

April 29, 2022

Shareholders of the U.S.’ big three COVID-19 vaccine makers have voted no on proposals asking the companies to share their intellectual property with low- and middle-income countries (LMICs) so that those countries could make their own versions of the vaccines. Source: Drug Industry Daily

Read More

Lilly’s Tirzepatide Helps Shed Pounds in Phase 3 Study

April 28, 2022

Eli Lilly has reported that its investigational once-weekly injectable treatment, tirzepatide, led to significant weight loss in obese and overweight patients in a late-stage study. Source: Drug Industry Daily

Read More

FDA Guidances Focus on Trials of Crohn’s Disease, Ulcerative Colitis Drugs

April 28, 2022

Trials of drugs to treat Crohn’s disease should add reduction of intestinal inflammation to their symptom-relief endpoints, according to an FDA draft guidance released Thursday in tandem with a draft guidance for conducting ulcerative colitis trials. Source: Drug Industry Daily

Read More

Amgen Faces Potential $7.1 Billion IRS Fine; Are Other Drugmakers at Risk?

April 28, 2022

Amgen disclosed this week that the Internal Revenue Service (IRS) is seeking $7.1 billion in back taxes and fines relating to how the drugmaker split profits between its U.S. and Puerto Rican manufacturing hubs. Source: Drug Industry Daily

Read More

IQVIA Issues Report Analyzing Unprecedented Speed of COVID-19 Vaccine Trials

April 28, 2022

IQVIA has come out with a new report that looks back at the historic timelines achieved by the COVID-19 vaccine trials, outlining lessons learned from the unprecedented research effort that have application now and in future research. Source: Drug Industry Daily

Read More

FDA Under Pressure to Grant Swift EUA for Moderna’s Vaccine for Young Children

April 28, 2022

Moderna announced yesterday that it has filed for FDA Emergency Use Authorization (EUA) of its two-dose COVID-19 vaccine in children less than six years old as the FDA comes under intense pressure from many sides to swiftly authorize the vaccine for this population. Source: Drug Industry Daily

Read More
Older Posts »

Recent Posts

  • FDA Approves New Safety Warning and Revised Indication that Limits Use for Elevidys Following Reports of Fatal Liver Injury
  • Longtime FDA Innovator Appointed as Director of Center for Drug Evaluation and Research
  • HHS Advances Women’s Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy
  • FDA Awards Second Batch of National Priority Vouchers
  • FDA Warns Companies Over Illegal Marketing of Botox and Related Products

Archives

  • November 2025
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • April 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • November 2024
  • October 2024
  • September 2024
  • August 2024
  • July 2024
  • June 2024
  • May 2024
  • April 2024
  • March 2024
  • February 2024
  • January 2024
  • December 2023
  • November 2023
  • October 2023
  • September 2023
  • August 2023
  • July 2023
  • June 2023
  • May 2023
  • April 2023
  • March 2023
  • February 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • October 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • February 2015
  • November 2014
  • May 2014
  • April 2014

Categories

  • BioPharma
  • BTS News
  • Devices & Diagnostics Letter
  • Drug GMP Report
  • Drug Industry Daily
  • FDAnews Device Daily Bulletin
  • FDAnews Drug Daily Bulletin
  • Generic Line
  • International Medical Device Regulatory Monitor
  • International Pharmaceutical Regulatory Monitor
  • News
  • QMN Weekly Bulletin
  • The Food & Drug Letter
  • The GMP Letter
  • Uncategorized
  • Washington Drug Letter

Company

BioLegacy Research
Toll Free: (866) 599-3019
Fax: (858) 605-5916
Email: info@biolegacyresearch.com

PARTNERING

Strategic collaborations are an important part of BioLegacy Research’s growth. Read More >>

CAREERS

To inquire about careers with BioLegacy Research. Read More >>
  • Services
  • Animal Species
  • About Us
  • Why BioLegacy
  • Request A Quote
  • Contact

Follow Us

Attribution

icons created by Freepik – Flaticon

© 2025 BioLegacy Research
Scroll To Top